GlassScriptPhysician profile
Megan E Griggs
NPI 1124566526
$12,812.25
in general payments reported to CMS, 2019-2025
34 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,361 · 2022: $2,414 · 2023: $2,426 · 2024: $2,856 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,845 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,844.66 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,271.70 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,719.08 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbott Laboratories | $1,138.43 | 2022-2025 | Infinity |
| Celgene Corporation | $687.39 | 2021-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $632.48 | 2021 | |
| Lundbeck LLC | $600.73 | 2021-2025 | Vyepti |
| Pfizer INC. | $492.75 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $463.66 | 2023-2025 | Acthar |
| Amgen INC. | $400.06 | 2021-2025 | Aimovig, Uplizna |
| Genentech USA, INC. | $357.97 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Lilly USA, LLC | $352.54 | 2021-2025 | Reyvow, Emgality, Kisunla |
| Acadia Pharmaceuticals INC | $328.71 | 2021-2025 | Nuplazid |
| Ucb, INC. | $308.17 | 2021-2025 | Rystiggo, Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $288.45 | 2022 | |
| Alexion Pharmaceuticals, INC. | $268.40 | 2022-2025 | Soliris, Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $207.21 | 2024-2025 | |
| Argenx US, INC. | $183.94 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Kyowa Kirin, INC. | $154.37 | 2021-2024 | Nourianz |
| Biogen, INC. | $136.05 | 2024-2025 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $124.85 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $110.27 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $104.94 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $93.24 | 2021 | |
| Tg Therapeutics, INC. | $81.38 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $60.09 | 2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $48.21 | 2024-2025 | Inbrija, Xeomin |
| E.R. Squibb & Sons, L.L.C. | $44.95 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $38.00 | 2025 | Crexont |
| Supernus Pharmaceuticals, INC. | $34.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.25 | 2023 | |
| Grifols USA, LLC | $16.99 | 2024 | Gamunex-C |
| Emd Serono, INC. | $14.17 | 2025 | |
| Impel Pharmaceuticals INC. | $12.81 | 2023 | Trudhesa |
| Csl Behring | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Griggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.